作者
Jennifer A Foltz, Brian T Hess, Veronika Bachanova, Nancy L Bartlett, Melissa M Berrien-Elliott, Ethan McClain, Michelle Becker-Hapak, Mark Foster, Timothy Schappe, Brad Kahl, Neha Mehta-Shah, Amanda F Cashen, Nancy D Marin, Kristen McDaniels, Chaz Moreno, Matthew Mosior, Feng Gao, Obi L Griffith, Malachi Griffith, Julia A Wagner, Narendranath Epperla, Amy D Rock, John Lee, Allegra A Petti, Patrick Soon-Shiong, Todd A Fehniger
发表日期
2021/6/15
期刊
Clinical Cancer Research
卷号
27
期号
12
页码范围
3339-3350
出版商
American Association for Cancer Research
简介
Purpose
N-803 is an IL15 receptor superagonist complex, designed to optimize in vivo persistence and trans-presentation, thereby activating and expanding natural killer (NK) cells and CD8+ T cells. Monoclonal antibodies (mAbs) direct Fc receptor–bearing immune cells, including NK cells, to recognize and eliminate cancer targets. The ability of IL15R agonists to enhance tumor-targeting mAbs in patients has not been reported previously.
Patients and Methods
Relapsed/refractory patients with indolent non-Hodgkin lymphoma were treated with rituximab and intravenous or subcutaneous N-803 on an open-label, dose-escalation phase I study using a 3+3 design (NCT02384954). Primary endpoint was maximum tolerated dose. Immune correlates were performed using multidimensional analysis via mass cytometry and cellular indexing of transcriptomes and epitopes by …
学术搜索中的文章
JA Foltz, BT Hess, V Bachanova, NL Bartlett… - Clinical Cancer Research, 2021